Join us at CKM Dialogues LIVE and delve into the cutting-edge world of Cardiovascular-Kidney-Metabolic (CKM) Syndrome management. This dynamic, evidence-driven CME activity sheds light on the latest strategies for tackling CKM syndrome—a complex condition at the intersection of heart failure, chronic kidney disease, and type 2 diabetes. While individual guidelines exist for each disease, comprehensive guidance on managing their overlap is limited. CKM Dialogues LIVE brings together a multidisciplinary team of experts to bridge this gap with real-world insights and discussions on emerging therapies.

In this 60-minute interactive session, Therapeutic Strategies for Cardiovascular-Kidney-Metabolic Syndrome: Addressing the Interconnected Triad of Heart Failure, Chronic Kidney Disease, and Diabetes, you’ll explore the metabolic mechanisms driving CKM syndrome and examine current and novel treatments. Held during the prestigious 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, this CME breakfast symposium empowers learners to rethink treatment approaches and tailor therapies for the best patient outcomes. Don’t miss this opportunity to advance your expertise in CKM syndrome with expert-led, practical, and concise content!

Earn up to 1.0 ACCME/ABIM MOC/EBAC/AAPA/ANCC/APE/CDR credit/contact hour.

This activity is intended for primary care physicians and other members of the multidisciplinary, interprofessional healthcare team in the U.S who care for patients with cardiovascular-kidney-metabolic syndrome.

After completing this activity, the participant should be better able to:

• Describe the complex interplay between CKD, HF, and T2D in the context of cardiovascular-kidney-metabolic syndrome.
• Analyze the epidemiological trends and pathophysiological mechanisms underlying the interconnectedness of HF, CKD, and T2D, and their implications for patient prognosis and quality of life.
• Evaluate the current evidence base supporting emerging therapeutic strategies, including sodium-glucose cotransporter 2 (SGLT2) inhibitors and aldosterone synthase inhibitors (ASIs), for managing cardiovascular-kidney-metabolic syndrome, with a focus on their potential to mitigate morbidity and mortality.
• Formulate evidence-based treatment plans for patients with cardiovascular-kidney-metabolic syndrome that consider the complex interactions between HF, CKD, and T2D to enhance patient quality of life

In support of improving patient care, Medical Learning InstituteInc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

This activity is provided by MLI

Physician Continuing Medical Education
Medical Learning Institute Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

EBAC Credit
Medical Learning Institute Inc. is an EBAC^® accredited provider effective October 2023. 

EBAC holds an agreement on mutual recognition of substantial equivalency with the Accreditation Council of CME (ACCME) and converts certificates for live educational events in the US, issued by ACCME accredited providers to European participants, in EBAC certificates (on request of the participants).

Dietitian Continuing Professional Education Units (CPEUs)

Medical Learning Institute Inc. is a Continuing Professional Education (CPE) Accredited provider with the Commission on Dietetic Registration (CDR).

CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activity/material.

Physician Associate  
Medical Learning Institute Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.5 contact hour in the area of pharmacology.

Continuing Pharmacy Education
Medical Learning Institute Inc. designates this application-based continuing education activity for 1.0 contact hour (0.1CEU) of the Accreditation Council for Pharmacy Education.

UAN: JA0007322-0000-24-091-L01-P

Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Chair/Planner/Presenter
Jay H. Shubrook, DO, FACOFP, FAAFP, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: Abbott, Bayer, Eli Lilly, Madrigal, Novo Nordisk

The following relationships have ended within the last 24 months:Consultant/Advisor: Nevro (ended 6/2023)

Planner/Presenter
Jennifer B. Green, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Mineralys, Novo Nordisk, Pfizer, Valo, Vertex

Research Funding: Bluedrop, Boehringer Ingelheim, Lilly, Merck, Roche

Planner/Presenter
Pam R. Taub, MD, FACC, FASPC, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: Amgen, Bayer, Boehringer Ingelheim, Edwards, Esperion, Jazz, Lilly, Medtronic, Merck, Novartis, Novo Nordisk, Sanofi

Contracted Researcher: Amgen, Merck, Novartis

The following relationships have ended within the last 24 months:

Consultant/Advisor: Amarin (ended 4/2024)

Contracted Researcher: Argenx (ended 1/2024)

Planner/Presenter
Matthew R. Weir, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Mineralys, Novo Nordisk

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.